Aim: Tolterodine is an anticholinergic drug used for the treatment of overactive bladder. We evaluated the effects of tolterodine on clinical symptoms and compared its efficacy with that of oxybutynin in terms of bladder capacity, bladder wall thickness, and post-void residual volume in children with overactive bladder.
Material And Methods: Twenty-six patients who were treated with tolterodine for overactive bladder (20 girls, mean age 8.0±2.2 years) were evaluated retrospectively. Twenty patients with overactive bladder who had undergone oxybutynin treatment (15 girls, mean age 7.6±1.8 years) served as the control group. Dysfunctional voiding symptom scoring was used to evaluate the clinical response to tolterodine. To investigate the effect of treatment on the bladder, ultrasonographic data at baseline and the third month were compared with the oxybutynin group.
Results: The dysfunctional voiding symptom scores significantly decreased after the third month of tolterodine treatment (p<0.001). Bladder capacity significantly increased (p<0.001), and filled bladder wall thickness decreased (p=0.007); however, post-void residual volumes significantly increased (p<0.001) at the third month. No serious adverse effects were recorded during tolterodine treatment. The increase in bladder capacity at the third month in the tolterodine group was similar to that in the oxybutynin group (p=0.77), but the decrease in filled bladder wall thickness was significantly greater in the tolterodine group (p=0.019).
Conclusion: Tolterodine remarkably ameliorates the clinical symptoms of overactive bladder in a short time, and seems to be as effective as oxybutynin for the treatment of overactive bladder in children. Its effect on reduction of bladder wall thickness appears to be superior to that of oxybutynin.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7536450 | PMC |
| http://dx.doi.org/10.14744/TurkPediatriArs.2020.98215 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Role of detrusor overactivity and interval between bladder sensations on the severity of overactive bladder symptoms in patients with multiple sclerosis.
Fr J Urol
December 2024
Sorbonne University, GRC 01, GREEN Group of clinical REsEarch in Neurourology, AP-HP, Hôpital Pitié Salpétrière, F-75013 Paris, France.
Purpose: This study aimed to assess the relationship between kinetics of bladder sensations perception, detrusor overactivity (DO), and severity of overactive bladder (OAB) symptoms in patients with multiple sclerosis (PwMS).
Methods: All PwMS who underwent urodynamic assessment including three cystometries (20 ml/min, 100 ml/min, and 100 ml/min with 4°C fluid) between June 2020 and October 2022 were included in this retrospective study. Data collected were bladder diaries, symptoms assessed with Urinary Symptoms Profile (USP), bladder sensations with first desire to void (FDV) and strong desire to void (SDV) during the 20ml/min cystometry, and presence of DO.
Can the Bladder Itself "Measure" Volume, and Thereby Help to Determine When Initiation of Voiding Should Occur? ICI-RS 2024.
Neurourol Urodyn
December 2024
Desai Sethi Institute of Urology, University of Miami Miller School of Medicine, Miami, Florida, USA.
Aims: To answer the question of whether the bladder itself can to any extent control or modulate the initiation of voiding.
Methods: This subject was discussed at the International Consultation on Incontinence-Research Society (ICI-RS) 2024 conference in Bristol, UK in a proposal session.
Results: Cells in the bladder wall sense the local environment via a diverse array of ion channels and receptors which together provide input to motor-sensory and signal transduction mechanisms.
Purpose: To assess efficacy and safety of URO-902, an investigational gene therapy expressing the α subunit of the large-conductance Ca-activated K channel, in a phase 2a placebo-controlled trial in women with overactive bladder (OAB).
Materials And Methods: Women, 40‒79 years, with OAB and urge urinary incontinence (UUI) who were refractory to OAB medications were randomized to single-dose URO-902 24 and 48 mg or placebo administered by intradetrusor injection via cystoscopy under local anesthesia. Efficacy endpoints included change from baseline to week 12 in mean daily micturitions, urgency episodes, UUI episodes, and patient-reported outcomes.
Re: Anirban Dey, Georgios Georgiadis, Justin Umezurike, et al. Mirabegron Versus Placebo and Other Therapeutic Modalities in the Treatment of Patients with Overactive Bladder Syndrome-A Systematic Review. Eur Urol Focus. In press. https://doi:10.1016/j.euf.2024.09.012.
Eur Urol Focus
December 2024
Department of Pediatric Surgery, Chengdu Women's and Children's Central Hospital, University of Electronic Science and Technology of China, Chengdu, China. Electronic address:
A Multicenter Prospective Cohort Study of Antibiotics for OnabotulinumtoxinA.
Urogynecology (Phila)
December 2024
From the University of Southern California, Los Angeles, CA.
Importance: Urinary tract infection (UTI) is the most common complication of intradetrusor onabotulinumtoxinA (BTX-A) injection. Despite this, there are no evidence-based guidelines on antibiotic prophylaxis.
Objectives: Our primary aim was to determine whether antibiotic prophylaxis decreased symptomatic, culture-proven UTI rates within 6 weeks of intradetrusor BTX-A injection.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!